Telix Pharmaceuticals (NASDAQ:TLX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 6th. Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Finally, UBS Group lowered their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Telix Pharmaceuticals Stock Performance

Shares of Telix Pharmaceuticals stock opened at $7.31 on Wednesday. The business has a fifty day simple moving average of $8.51 and a 200-day simple moving average of $10.43. Telix Pharmaceuticals has a fifty-two week low of $7.16 and a fifty-two week high of $30.36.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in TLX. Millennium Management LLC bought a new position in Telix Pharmaceuticals during the third quarter worth $1,883,000. Pier Capital LLC acquired a new position in Telix Pharmaceuticals in the 2nd quarter valued at approximately $3,037,000. Portland Investment Counsel Inc. acquired a new position in Telix Pharmaceuticals in the 3rd quarter valued at approximately $1,225,000. Lazard Asset Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter worth approximately $1,097,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.